Plain-English translation of NCT06938685 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether NeoThelium FT, a tissue-engineered treatment, can help diabetic foot ulcers heal better and faster when used alongside standard wound care. Researchers want to understand if adding this new treatment to regular care — like wound cleaning, proper dressings, and offloading pressure — makes a real difference for people whose ulcers aren't healing well on their own. The study will follow patients for about 12 weeks to see how many ulcers close completely.
Many people with diabetes develop foot ulcers that heal very slowly or not at all, even with careful standard care. This medication is designed to boost the body's natural healing process, and researchers want to confirm whether it actually works and to help insurance companies make informed decisions about coverage.
You likely qualify if…
You likely don't qualify if…
You'll first go through a 2-week screening phase where doctors will check your wound and confirm you're eligible. Then you'll be randomly assigned to either standard wound care alone, or standard care plus weekly applications of the new treatment for up to 12 weeks. If you're in the standard-care-only group and your wound hasn't fully closed after about 12 weeks, you may be able to switch to the treatment group. You'll have regular clinic visits to monitor your wound's progress, and doctors will measure healing and assess your pain throughout the study.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States